SCHEMBL1553071

SCHEMBL1553071

CCc1c(C(=O)O)[nH]c2ccc(O)cc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.71
CYP1A2 P05177 2/20 0.71
CYP2C9 P11712 2/20 0.71
CYP2C19 P33261 2/20 0.71
PRNP P04156 1/20 0.71
PPARG P37231 1/20 0.71
HIF1A Q16665 1/20 0.71
RXFP1 Q9HBX9 1/20 0.71
NR2E3 Q9Y5X4 1/20 0.71
NCOR2 Q9Y618 1/20 0.71
KDM4E B2RXH2 4/20 0.52
HSD17B10 Q99714 4/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 3/20 0.49
RAD52 P43351 1/20 0.48
BLM P54132 1/20 0.48
GAA P10253 3/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
HTR1D P28221 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5023538 0.88 PRNP (0.58) NPSR1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL3107611 0.84 PRNP (0.71) NPSR1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL2538695 0.83 PRNP (0.69) NPSR1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL1894184 0.83 RXFP1 (1.00) NPSR1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL8959541 0.83 PRNP (0.69) NPSR1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL31120728 0.81 PRNP (0.61) NPSR1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL3036074 0.81 KDM4E (0.74) NPSR1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL5962663 0.80 ALDH1A1 (0.60) NPSR1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL7958149 0.80 PRNP (0.64) NPSR1CYP1A2CYP2C9CYP2C19PRNP
SCHEMBL6517272 0.80 PRNP (0.64) NPSR1CYP1A2CYP2C9CYP2C19PRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968967-B1 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS HOFFMANN LA ROCHE (CH) 2011-04-27 EP disclosed
EP-1960383-B1 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-04-28 EP disclosed
US-7538101-B2 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-05-26 US disclosed
US-20090118349-A1 BIS-ALKYLATING AGENTS AND THEIR USE IN CANCER THERAPY ONCO-PHARMAKON INCORPORATED (US) 2009-05-07 US disclosed
EP-1968967-A1 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2008-09-17 EP disclosed
EP-1960383-A1 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES F. Hoffmann-la Roche AG (CH) 2008-08-27 EP disclosed
US-7388095-B2 5-substituted indole-2-carboxamide derivatives HOFFMANN-LA ROCHE INC. (US) 2008-06-17 US disclosed
EP-1761519-B1 INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2008-05-07 EP disclosed
US-7361682-B2 Indole derivatives as H3 inverse agonists HOFFMANN-LA ROCHE INC. (US) 2008-04-22 US disclosed
WO-2007063000-A1 5-SUBSTITUTED INDOLE-2-CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed
WO-2007062997-A1 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed
US-20070123526-A1 1,1-Dioxo-thiomorpholinyl indolyl methanone derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-05-31 US disclosed
US-20070123525-A1 5-Substituted indole-2-carboxamide derivatives HOFFMANN-LA ROCHE INC. 2007-05-31 US disclosed
EP-1761519-A1 INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP disclosed
WO-2005123716-A1 INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-29 WO disclosed
US-20050282864-A1 Indole derivatives as H3 inverse agonists HOFFMANN-LA ROCHE INC. 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118349-A1 BIS-ALKYLATING AGENTS AND THEIR USE IN CANCER THERAPY UNG, MPG, DIMT1 NPSR1 3379/4885CYP1A2 1500/4885CYP2C9 1084/4885
US-20050282864-A1 Indole derivatives as H3 inverse agonists HRH3, HRH4, ADRB1 NPSR1 29/4885CYP1A2 641/4885CYP2C9 1359/4885
US-20070123525-A1 5-Substituted indole-2-carboxamide derivatives HRH4, HRH3, HCAR2 NPSR1 32/4885CYP1A2 359/4885CYP2C9 521/4885
US-20070123526-A1 1,1-Dioxo-thiomorpholinyl indolyl methanone derivatives MTNR1A, HTR1A, HRH4 NPSR1 81/4885CYP1A2 280/4885CYP2C9 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.